3 Soaring Stocks That May Have More Upside Ahead

The article highlights three biotech and semiconductor stocks that have more than doubled in the past 12 months but may have further upside potential. Abivax is advancing obefazimod for ulcerative colitis with strong clinical results. Krystal Biotech is generating strong revenue growth from its approved DEB treatment Vyjuvek with significant market expansion opportunities. Marvell Technology is capitalizing on AI infrastructure spending demand for custom chips as an alternative to Nvidia's GPUs.

07/07/2026, 7:15 PM • The Motley Fool

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax SA resumed trading of its ordinary shares on Euronext Paris on July 1, 2026, following a temporary halt. The company announced the pricing of an oversubscribed and upsized public offering of American Depositary Shares, increased from the previously announced $600M to $800M at $125.00 per share.

07/01/2026, 8:56 AM • GlobeNewswire

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax SA announced a temporary trading halt of its ordinary shares on Euronext Paris effective July 1, 2026, from market opening at 9:00 a.m. CEST. The halt is in connection with the company's public offering of American Depositary Shares in the United States to allow for allocation confirmation and pricing announcement. Trading is expected to resume at approximately 3:30 p.m. CEST the same day.

07/01/2026, 1:30 AM • GlobeNewswire

Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris

Abivax SA announced a temporary suspension of its ordinary shares trading on Euronext Paris starting July 1, 2026 at market opening. The suspension is related to the company's public offering of American Depositary Shares (ADS) in the United States to confirm investor allocations and announce final offering terms. Trading is expected to resume around 15:30 CEST the same day.

07/01/2026, 1:30 AM • GlobeNewswire

What's Going On With Abivax Stock On Thursday?

Abivax stock rose 3.46% on Thursday despite concerns following the release of Phase 3 trial data for obefazimod in ulcerative colitis. While the drug met primary endpoints with remission rates exceeding 50%, reported cancer cases during the trial have raised safety concerns among investors. The stock trades below its moving averages, with momentum indicators suggesting weakness.

06/04/2026, 10:35 AM • Benzinga

This Stock Is Up 1,000% Over the Past Year. Is There More Upside Ahead?

Abivax, a French biotech company, saw its stock surge 1,000% over the past year following strong phase 3 results for obefazimod, a non-immunosuppressant ulcerative colitis treatment. However, recent maintenance trial data revealed safety concerns including cancer cases, causing a sharp stock decline. The author argues the market may be overreacting, noting that cancer cases were mostly in older patients and may be unrelated to the drug, while obefazimod still shows strong efficacy and oral convenience advantages.

06/03/2026, 5:15 PM • The Motley Fool

2 Stocks That Could Realistically Double by 2030

Abivax and Viking Therapeutics are two biotech companies that could potentially double in value by 2030 if their leading drug candidates succeed in clinical trials and regulatory approval. Abivax is developing obefazimod for ulcerative colitis, while Viking Therapeutics is advancing VK2735 for weight loss treatment. Both stocks carry significant risk due to their clinical-stage status and lack of approved products.

05/22/2026, 3:15 AM • The Motley Fool

Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032

The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

04/10/2026, 4:43 AM • GlobeNewswire

Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears

Abivax CEO Marc de Garidel downplayed acquisition rumors and indicated the company plans to pursue equity and debt financing after releasing key Phase 3 trial data for obefazimod in late Q2 2026. With $614.42 million in cash providing runway into Q4 2027, the French biotech aims to strengthen its financial position ahead of potential FDA approval and commercialization, while seeking commercial partners for markets outside the U.S.

03/24/2026, 1:53 PM • Benzinga

2 Healthcare Stocks to Buy Before They Get Bought Out

Abivax and Nektar Therapeutics are clinical-stage biotech companies with promising drug candidates that could make them attractive acquisition targets. Abivax is developing obefazimod for inflammatory diseases with phase 3 trial data expected in Q2, while Nektar's rezpegaldesleukin shows strong potential for eczema treatment. Both companies have sufficient funding and could be acquired by major pharmaceutical companies at premium valuations.

03/20/2026, 5:34 AM • The Motley Fool

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter

Cormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage therapies for neurological disorders with strong cash reserves of $926 million.

03/16/2026, 6:23 PM • The Motley Fool

Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline

AstraZeneca has exclusive access to Abivax's data room until March 23 as the leading bidder for the French biotech company, which surged 1,600% in 2025 following positive Phase 3 trial results for its ulcerative colitis drug obefazimod. If AstraZeneca fails to submit an offer by the deadline, Eli Lilly and other interested parties could re-enter negotiations. AstraZeneca may have advantages due to its European status and CEO's existing relationship with Abivax's leadership.

03/12/2026, 6:46 AM • Benzinga

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax presented 22 abstracts at ECCO 2026 demonstrating obefazimod's anti-fibrotic activity in preclinical models, favorable safety profile comparable to placebo, and rapid symptomatic improvements in ulcerative colitis patients. Biomarker data showed upregulation of miR-124 and reduction of inflammatory cytokines IL-17A and IL-6. The company expects Phase 3 maintenance trial results in Q2 2026 and Phase 2b ENHANCE-CD trial results in Q4 2026.

02/21/2026, 6:00 AM • GlobeNewswire

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

For investors who missed Eli Lilly's impressive run, two smaller biotech companies offer potential alternatives: Viking Therapeutics is developing VK2735, a weight-loss drug similar to Eli Lilly's Zepbound with phase 3 results expected next year, while Abivax is testing obefazimod for ulcerative colitis with maintenance study results planned for Q2. Both stocks carry high risk but could deliver significant rewards if their clinical trials succeed.

02/10/2026, 8:11 PM • The Motley Fool

Better Long-Term Buy: This Emerging Player or the Industry Leader?

AbbVie, a pharmaceutical giant with strong immunology products like Skyrizi and Rinvoq, is compared against Abivax, an emerging biotech company developing obefazimod for ulcerative colitis. AbbVie offers stability, consistent revenue, and dividend income, making it suitable for risk-averse investors. Abivax presents higher risk but significant upside potential if its drug successfully reaches the market, with possible acquisition prospects.

01/30/2026, 3:30 PM • The Motley Fool